Resources Repository
-
ArticlePublication 2007Economic Evaluation of Hepatitis B Vaccination in Low-Income Countries: Cost-Effectiveness Affordability Curves
In the face of uncertainties about both the health and economic consequences of a vaccine …
In the face of uncertainties about both the health and economic consequences of a vaccine program, as well as the availability and magnitude of resources needed to fund the program, cost-effectiveness affordability curves can provide information to decision-makers about the probability that a program will be both cost-effective and affordable: these are distinct but equally relevant considerations in resource-poor settings. This paper describes the application of this method to assess a hepatitis B vaccination program in the…
Microsimulation | Mathematical Models | State-Transition | Sub-Saharan Africa | Costing Methods | Cost-Effectiveness Analysis | Infectious Diseases | Health Systems | Economics/Finance | Health/Medicine -
ArticlePublication 2002Empirically Calibrated Model of Hepatitis C Virus Infection in the United States
This article presents an epidemiologic model of hepatitis C in the United States. The authors …
This article presents an epidemiologic model of hepatitis C in the United States. The authors used empirical calibration of model parameters to gain insights into uncertainty in the natural history of hepatitis C and to improve future projections. The authors identified model inputs by way of a systematic review. Model simulations were conducted and model predictions were compared with epidemiologic data on infection prevalence and mortality from liver cancer. Goodness-of-fit criteria were used to identify…
Mathematical Models | Calibration/Validation | State-Transition | North America | Infectious Diseases | Chronic Disease/Risk | Health/Medicine -
ArticlePublication 2023Cost-Effectiveness of Pharmacist Prescribing for Managing Hypertension
This study estimates the cost-effectiveness of implementing a pharmacist-prescribing intervention to improve blood pressure control …
This study estimates the cost-effectiveness of implementing a pharmacist-prescribing intervention to improve blood pressure control in the US. A cost-effectiveness analysis was conducted using a Markov model based on the pharmacist-prescribing intervention used in The Alberta Clinical Trial in Optimizing Hypertension (or RxACTION). Outcomes included cardiovascular (CV) events, end-stage kidney disease events, life years, quality-adjusted life years (QALYs), lifetime costs, and lifetime incremental cost-effectiveness ratio (ICER). Costs were based on reimbursement rates, published literature, national…
Mathematical Models | State-Transition | North America | Cost-Effectiveness Analysis | Chronic Disease/Risk | Clinical Care | Health/Medicine -
ArticlePublication 2023Calibration and Validation of the Colorectal Cancer and Adenoma Incidence and Mortality (CRC-AIM) Microsimulation Model Using Deep Neural Networks
This study explores the efficacy of machine learning (ML)-based emulators in calibrating complex microsimulation models, …
This study explores the efficacy of machine learning (ML)-based emulators in calibrating complex microsimulation models, using the Colorectal Cancer (CRC)-Adenoma Incidence and Mortality (CRC-AIM) model as a case study. ML algorithms, including deep neural networks (DNN), were trained and compared using data generated from the CRC-AIM model to predict various outcomes. The DNN outperformed other algorithms and efficiently predicted outcomes, reducing computational burden significantly. The calibrated CRC-AIM model demonstrated cross-model validity against established CISNET models…
Microsimulation | Calibration/Validation | North America | Chronic Disease/Risk | Health/Medicine -
ArticlePublication 2022Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face …
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face of uncertainty. This study aimed to quantify consequences of approving therapies or pursuing further research. The authors used a cohort state-transition model for hospitalized patients with COVID-19 to estimate quality-adjusted life-years (QALYs) and costs associated with multiple drug regimens and usual care. For each they assessed immediate approval, use only in research, emergency use authorization or reject. They conducted cost-effectiveness…
Benefit-Cost Analysis | State-Transition | North America | Value of Information | Infectious Diseases | Policy/Regulation | Economics/Finance | Europe -
ArticlePublication 2022Early HPV Natural History Transitions
Microsimulation models used to evaluate the cost-effectiveness of novel cervical cancer screening technologies rely on …
Microsimulation models used to evaluate the cost-effectiveness of novel cervical cancer screening technologies rely on accurate transition risks for human papillomavirus (HPV) infection, persistence (or absence of HPV clearance), progression to precancerous lesions, and invasion. To inform the refinement of such models, we compared the early natural history of HPV types using prospective data from immunocompetent women in the Guanacaste Natural History Study, the ASCUS-LSIL Triage Study, and the Costa Rica HPV Vaccine Trial. We…
Microsimulation | Mathematical Models | North America | Cost-Effectiveness Analysis | Infectious Diseases | Latin America & Caribbean -
ArticlePublication 2019Estimation of Eating Disorders Prevalence by Age and Associations with Mortality in a Simulated Nationally Representative U.S. Cohort
This analysis models the individual-level disease dynamics of eating disorders (ED) in the United States, …
This analysis models the individual-level disease dynamics of eating disorders (ED) in the United States, and estimates the association of increased treatment coverage with ED-related mortality. Using an individual-level Markov state transition model calibrated to nationally-representative US survey data from 2007 and 2011, the authors simulated a virtual cohort of 100,000 individuals (50% male) from birth to age 40 years and modelled 4 ED diagnoses: anorexia nervosa, bulimia nervosa, binge eating disorder, and other specified…
Microsimulation | Calibration/Validation | North America | Health Outcomes | Child/Nutrition | Mental Health -
ArticlePublication 2019Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity
This analysis estimates state-specific and demographic subgroup-specific trends and projections of the prevalence of categories …
This analysis estimates state-specific and demographic subgroup-specific trends and projections of the prevalence of categories of body-mass index (BMI) in the United States. Self-reported BMI from the Behavioral Risk Factor Surveillance System Survey (1993-1994 and 1999-2016) were obtained and corrected for quantile-specific self-reporting bias. Multinomial regressions were then fitted for each state and subgroup to estimate the prevalence of four BMI categories from 1990 through 2030: underweight or normal weight (BMI <25), overweight (25 to…
Mathematical Models | Calibration/Validation | North America | Health Outcomes | Chronic Disease/Risk | Social Determinants -
ArticlePublication 2022Excess Mortality and Elevated Body Weight in the U.S.
This analysis estimates excess mortality associated with elevated body weight in the United States by …
This analysis estimates excess mortality associated with elevated body weight in the United States by state and demographic subgroup. The authors developed a nationally-representative microsimulation (individual-level) model of US adults between 1999 and 2016, based on risk factor data from the Behavioral Risk Factor Surveillance System and body-mass index (BMI) mortality hazard ratios from a global pooling dataset. The model was calibrated to empirical all-cause mortality rates from CDC WONDER by state and subgroup, and…
Microsimulation | Calibration/Validation | North America | Health Outcomes | Chronic Disease/Risk | Social Determinants